Population Pharmacokinetics of Sildenafil in Dogs With Naturally Occurring Pulmonary Hypertension
Open Access
- 24 February 2026
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (3) , 267-273
Abstract
The pharmacokinetics of sildenafil are ill‐defined in dogs with naturally occurring pulmonary hypertension (PH). Because the plasma concentrations of sildenafil have not been reported for dogs with this disease, this study aimed to describe the population pharmacokinetics of sildenafil in a sample of dogs with PH. Twenty client‐owned dogs with spontaneous PH associated with diverse comorbidities and receiving orally administered sildenafil were enrolled in a prospective, open‐label, steady‐state population pharmacokinetic study. Dogs underwent a sparse‐sampling blood collection protocol after the morning dose of sildenafil. Plasma sildenafil concentrations were determined using high‐pressure liquid chromatography and mass spectrometry. Population pharmacokinetic analysis with nonlinear mixed effects modeling was performed, and selected covariates were evaluated in the model. Sildenafil was rapidly absorbed (absorption half‐life 1.1 h) but variable (CV 94%) and reached maximal plasma concentrations at 2.51 h. The estimated elimination half‐life was 2.9 h. However, substantial individual variability in pharmacokinetics of sildenafil was evident, unexplained by the covariates examined, and attributed primarily to the high variability in absorption. This finding supports the need for a large‐scale study to identify the source of this variability to better guide therapy in poor responders to initial therapy with this drug.Keywords
Funding Information
- American College of Veterinary Internal Medicine
This publication has 17 references indexed in Scilit:
- 〈1225〉 Validation of Compendial Procedures2021
- ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogsJournal of Veterinary Internal Medicine, 2020
- Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertensionScientific Reports, 2019
- Pharmacokinetics of single‐dose sildenafil administered orally in clinically healthy dogs: Effect of feeding and dose proportionalityJournal of Veterinary Pharmacology and Therapeutics, 2018
- Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models2014
- Identification of PDE5A:E90K: A Polymorphism in the Canine Phosphodiesterase 5A Gene Affecting Basal cGMP Concentrations of Healthy DogsJournal of Veterinary Internal Medicine, 2014
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2012
- Diagnosing Model DiagnosticsClinical Pharmacology & Therapeutics, 2007
- A pragmatic approach to the design of population pharmacokinetic studiesThe AAPS Journal, 2005
- Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and manXenobiotica, 1999